Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with Schedule ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.7 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Gujarat Terce Laboratories approved the Unaudited Standalone Financial Results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell to Rs. 1,085.36 lakhs from Rs. 1,188.88 lakhs in Q1 FY25, an about 8.7% year-on-year decline. The company reported a net loss of Rs. 4.35 lakhs in Q1 FY26 versus a loss of Rs. 7.76 lakhs in the year-ago quarter, narrowing slightly. For the full FY25, the company had a loss of Rs. 97.87 lakhs on revenue of Rs. 5,019.52 lakhs. Statutory auditors M.A. Shah & Co. issued a clean (unmodified) limited review report. The Board also reconstituted its Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, all now comprising independent directors and the Managing Director.
The company continues to post quarterly losses, though the loss has narrowed slightly compared to Q1 FY25, indicating limited improvement in profitability. Declining top-line revenue combined with persistent losses is a weak signal for shareholders, though there are no auditor qualifications or going-concern flags at this stage.